Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

Rhythm Pharmaceuticals is supported by a clear commercial and clinical thesis: IMCIVREE has already shown statistically significant efficacy in acquired hypothalamic obesity, including a -18.8% placebo-adjusted BMI reduction in TRANSCEND and consistent benefits in hyperphagia, body composition, and quality of life. Its outlook is further strengthened by the Japan approval in late August 2026, a market with an estimated 5,000 to 8,000 patients, plus an expected launch before the end of 2026 and an expanding global opportunity in rare genetic obesity. The company also has multiple growth catalysts, including early-stage MC4R assets RM-718 and bivamelagon and a potential congenital hyperinsulinism program, while U.S. launch momentum already exceeded 150 patient start forms within the first 6 weeks.

Rhythm Pharmaceuticals is exposed to a fragile risk-reward profile because its valuation depends heavily on setmelanotide, yet only a 60% probability of approval is assigned to PWS and 40% to bivamelagon in HO, while the downside case drops sharply to $67 with just 5% probability assumptions for several programs. Commercial execution is also uncertain: IMCIVREE only began active commercialization in the US and EU in 2022, and a slower-than-expected sales ramp could be compounded by competition from the GLP-1 class and long-term pricing pressure. Beyond near-term sales, clinical setbacks, regulatory uncertainty, and intellectual property risk could limit expansion beyond current indications and leave the company vulnerable to dilution risk.